AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36265052 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.60 g/kg alcohol
Number of subjects: 24
Study 36265052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 36265076 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection 2 mg every 4 weeks
Number of subjects: 255
Study 36265076 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection 2 mg every 8 weeks
Number of subjects: 255
Study 36265076 — intervention group
Group type: COMPARATOR
Intervention: Laser control
Number of subjects: 255
Study 36265087 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax 600 mg + Idasanutlin 150 mg
Number of subjects: 56
Study 36265087 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax 600 mg + Idasanutlin 200 mg
Number of subjects: 56
Study 36265087 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (various doses) + Idasanutlin (days 1-5 in 28-day cycles)
Number of subjects: 56
Study 36265087 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with IDH1/2 mutations
Number of subjects: 56
Study 36265087 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RUNX1 mutations
Number of subjects: 56
Study 36265087 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with TP53 mutations
Number of subjects: 56
Study 36265128 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 in CLL patients
Number of subjects: 256
Study 36265128 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 256
Study 36265128 — intervention group
Group type: EXPERIMENTAL
Intervention: Age over 70 years
Number of subjects: 256
Study 36265128 — intervention group
Group type: EXPERIMENTAL
Intervention: Any treatment for CLL in the last 12 months
Number of subjects: 256
Study 36265128 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 severity (severe)
Number of subjects: 256
Study 36265128 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 severity (critical)
Number of subjects: 256
Study 36265185 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D echocardiographic imaging and assessment of RV global area strain (AS) at baseline and 6-month follow-up.
Number of subjects: 95
Study 36265185 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in RV global AS over 6-month follow-up.
Number of subjects: 95
Study 36265185 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of changes in WHO class, BNP, and RV global AS.
Number of subjects: 95
Study 36265570 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of children with IEMs requiring a restricted diet
Number of subjects: 785
Study 36265677 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum cervical length measurement at 8 hours
Number of subjects: 1384
Study 36265677 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum cervical length measurement at 24 hours
Number of subjects: 1384
Study 36265677 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum cervical length measurement at 48 hours
Number of subjects: 1384
Study 36265677 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum cervical length measurement at 6 weeks
Number of subjects: 1384
Study 36265677 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm birth screening based on history of short postpartum cervix
Number of subjects: 1384
Study 36265677 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm birth screening based on history of spontaneous preterm birth
Number of subjects: 1384
Study 36265677 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined screening of history of spontaneous preterm birth and short postpartum cervix
Number of subjects: 1384
Study 36265962 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Implantable Cardioverter-Defibrillator Therapy
Number of subjects: 0
Study 36265962 — intervention group
Group type: COMPARATOR
Intervention: Transvenous Implantable Cardioverter-Defibrillator Therapy
Number of subjects: 0
Study 36266001 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-detected sleep apnea (measured by weekly mean RDI)
Number of subjects: 411
Study 36266001 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly mean RDI of ≥45 episodes/h
Number of subjects: 411
Study 36266001 — intervention group
Group type: COMPARATOR
Intervention: Maximum RDI value during follow-up
Number of subjects: 411
Study 36266008 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 165
Study 36266153 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (this is an observational study with no intervention)
Number of subjects: 1000
Study 36266435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C-based estimation of glomerular filtration rate (eGFR)
Number of subjects: 0
Study 36266449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative carbohydrate loading
Number of subjects: 49
Study 36266642 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffractive trifocal intraocular lens (IOL)
Number of subjects: 80
Study 36266642 — intervention group
Group type: COMPARATOR
Intervention: Refractive bifocal intraocular lens (IOL)
Number of subjects: 80
Study 36266642 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffractive trifocal IOL
Number of subjects: 80
Study 36266642 — intervention group
Group type: COMPARATOR
Intervention: Refractive bifocal IOL
Number of subjects: 80
Study 36266939 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 15
Study 36266939 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 15
Study 36267207 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg)
Number of subjects: 104
Study 36267207 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg)
Number of subjects: 104
Study 36267207 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (4000 IU)
Number of subjects: 104
Study 36267207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 36267207 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and Vitamin D3
Number of subjects: 104
Study 36267207 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 104
Study 36267321 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-week group-format self-management intervention
Number of subjects: 453
Study 36267321 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 453
Study 36267356 — intervention group
Group type: EXPERIMENTAL
Intervention: Head computed tomography (CT) for assessment of hypoxic-ischaemic encephalopathy (HIE)
Number of subjects: 0
Study 36267356 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized protocol for evaluation of CT images
Number of subjects: 0
Study 36267663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus Letrozole
Number of subjects: 5
Study 36267741 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib 500 mg per day
Number of subjects: 53
Study 36268285 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer patients from Karachi
Number of subjects: 500
Study 36268539 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-atrial long-axis shortening (LA LAS) assessment
Number of subjects: 1235
Study 36268648 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapersonal and environmental factors
Number of subjects: 241
Study 36268648 — intervention group
Group type: EXPERIMENTAL
Intervention: Improving recreational access and self-efficacy
Number of subjects: 241
Study 36268822 — intervention group
Group type: EXPERIMENTAL
Intervention: General Antimicrobial Stewardship Program (ASP) with a bundle of 5 educational measures
Number of subjects: 14
Study 36268822 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental ASP with 1-to-1 educational interviews
Number of subjects: 14
Study 36268822 — intervention group
Group type: EXPERIMENTAL
Intervention: General ASP
Number of subjects: 14
Study 36268845 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary management of CIP
Number of subjects: 0
Study 36268941 — intervention group
Group type: EXPERIMENTAL
Intervention: AdaSim plus standard of care (SOC)
Number of subjects: 0
Study 36268941 — intervention group
Group type: COMPARATOR
Intervention: SOC alone
Number of subjects: 0
Study 36269092 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular Phase Stimulation (FS)
Number of subjects: 44
Study 36269092 — intervention group
Group type: COMPARATOR
Intervention: Luteal Phase Stimulation (LS)
Number of subjects: 44
Study 36269154 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorine 18
Number of subjects: 0
Study 36269382 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (ISO) injections
Number of subjects: 1
Study 36269426 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH) initiated within 6 hours of life
Number of subjects: 629
Study 36269426 — intervention group
Group type: COMPARATOR
Intervention: Maternities with <1999 annual births
Number of subjects: 629
Study 36269426 — intervention group
Group type: COMPARATOR
Intervention: Time interval >3 hours between birth and call for transfer
Number of subjects: 629
Study 36269426 — intervention group
Group type: COMPARATOR
Intervention: Time interval >3 hours between call for transfer and admission
Number of subjects: 629
Study 36269426 — intervention group
Group type: COMPARATOR
Intervention: Occurrence of an undesirable event during transfer
Number of subjects: 629
Study 36269503 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks (q2w)
Number of subjects: 917
Study 36269503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 917
Study 36269504 — intervention group
Group type: EXPERIMENTAL
Intervention: Worst Itch Scale
Number of subjects: 0
Study 36269504 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Global Impression of Disease
Number of subjects: 0
Study 36269530 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-chemotherapy IL-8
Number of subjects: 267
Study 36269530 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-chemotherapy TNF-α
Number of subjects: 267
Study 36269530 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy duration above 20 weeks
Number of subjects: 267
Study 36269530 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy dose
Number of subjects: 267
Study 36269595 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 2122
Study 36269595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2122
Study 36269660 — intervention group
Group type: EXPERIMENTAL
Intervention: Boron neutron capture therapy (BNCT) using l-boronophenylalanine-fructose (l-BPA-F)
Number of subjects: 249
Study 36269662 — intervention group
Group type: EXPERIMENTAL
Intervention: MyADHD intervention
Number of subjects: 5
Study 36269731 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgosedation (specifically ketamine)
Number of subjects: 134
Study 36269731 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative doses of ketamine
Number of subjects: 134
Study 36269797 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg/day orally; 14 days)
Number of subjects: 20
Study 36269797 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 20
Study 36269797 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA-seq and proteomic studies
Number of subjects: 20
Study 36269898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel) infusion (target dose 0.75 × 10^6 CAR+ T cells/kg)
Number of subjects: 48
Study 36269898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel) infusion
Number of subjects: 48
Study 36269899 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-adapted therapy (doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by interim PET), followed by additional cycles based on PET results.
Number of subjects: 94
Study 36269899 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-adapted therapy (doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by interim PET), followed by intensified treatment for PET2+ patients.
Number of subjects: 94
Study 36270020 — intervention group
Group type: EXPERIMENTAL
Intervention: QIDS
Number of subjects: 78
Study 36270020 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ
Number of subjects: 78
Study 36270020 — intervention group
Group type: EXPERIMENTAL
Intervention: CES-D
Number of subjects: 78
Study 36270020 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood Disorder Questionnaire (MDQ)
Number of subjects: 78
Study 36270020 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypomania Checklist (HCL)
Number of subjects: 78
Study 36270020 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Sleep
Number of subjects: 78
Study 36270020 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperament Traits
Number of subjects: 78
Study 36270063 — intervention group
Group type: EXPERIMENTAL
Intervention: High RNT (H-RNT)
Number of subjects: 124
Study 36270063 — intervention group
Group type: EXPERIMENTAL
Intervention: Low RNT (L-RNT)
Number of subjects: 124
Study 36270063 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 124
Study 36270474 — intervention group
Group type: EXPERIMENTAL
Intervention: Image guided intensity modulated radiotherapy (IG-IMRT)
Number of subjects: 0
Study 36270615 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight leg raise (SLR) maneuver during high-resolution manometry (HRM)
Number of subjects: 295
Study 36270615 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase of 11 mm Hg of peak IEP from baseline during SLR
Number of subjects: 295
Study 36270615 — intervention group
Group type: EXPERIMENTAL
Intervention: SLR maneuver
Number of subjects: 295
Study 36270733 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (750 mg every 2 weeks)
Number of subjects: 46
Study 36270753 — intervention group
Group type: EXPERIMENTAL
Intervention: Danvatirsen monotherapy
Number of subjects: 11
Study 36270753 — intervention group
Group type: EXPERIMENTAL
Intervention: Danvatirsen plus durvalumab combination therapy
Number of subjects: 11
Study 36270753 — intervention group
Group type: EXPERIMENTAL
Intervention: Danvatirsen monotherapy and combination therapy
Number of subjects: 11
Study 36270787 — intervention group
Group type: EXPERIMENTAL
Intervention: PIMSRA (Percutaneous IntraMyocardial Septal Radiofrequency Ablation)
Number of subjects: 82
Study 36270802 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention for pancreatic injury
Number of subjects: 88
Study 36270802 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of intra-abdominal abscess (IAA)
Number of subjects: 88
Study 36270802 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of intestinal fistula
Number of subjects: 88
Study 36270802 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock on admission
Number of subjects: 88
Study 36270802 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of abdominal suction drainage
Number of subjects: 88
Study 36270802 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index (BMI)
Number of subjects: 88
Study 36270802 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative hemorrhage (POH)
Number of subjects: 88
Study 36270803 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic bilateral deep brain stimulation (DBS) leads in the subthalamic nucleus (STN)
Number of subjects: 3
Study 36270895 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV-C (2 g/kg loading dose over 2 days, maximum 80 g/d; maintenance doses of 1 g/kg every 3 weeks)
Number of subjects: 0
Study 36270895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36270952 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA reconstruction approach 0.50/5 (slice thickness 0.50 mm and highest strength 5 ADMIRE IR)
Number of subjects: 15
Study 36270952 — intervention group
Group type: COMPARATOR
Intervention: CCTA reconstruction approaches (various)
Number of subjects: 15
Study 36270952 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA reconstruction approach 0.50/5
Number of subjects: 15
Study 36271011 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly nab-paclitaxel for three cycles
Number of subjects: 40
Study 36271062 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative near-infrared (NIR) lymphography with indocyanine green (ICG)
Number of subjects: 65
Study 36271062 — intervention group
Group type: COMPARATOR
Intervention: Standard D1 + LN dissection under white light
Number of subjects: 65
Study 36271158 — intervention group
Group type: EXPERIMENTAL
Intervention: ZED8 (monovalent antibody labeled with zirconium-89)
Number of subjects: 0
Study 36271384 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT)
Number of subjects: 39
Study 36271384 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline sympathetic tone (average SKNA ≥ 0.86 μV)
Number of subjects: 39
Study 36271404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored implementation approach
Number of subjects: 12
Study 36271404 — intervention group
Group type: COMPARATOR
Intervention: Standardized implementation approach
Number of subjects: 12
Study 36271419 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydration assessed through estimated osmolality (eOSM = 2Na + 2 K + glucose + urea)
Number of subjects: 165
Study 36271419 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydration during acute COVID-19 infection
Number of subjects: 165
Study 36271912 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (oral small molecule Janus kinase inhibitor)
Number of subjects: 0
Study 36272877 — intervention group
Group type: EXPERIMENTAL
Intervention: dTaP-IPV booster vaccine
Number of subjects: 0
Study 36272877 — intervention group
Group type: COMPARATOR
Intervention: No pertussis-containing vaccine
Number of subjects: 0
Study 36272997 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia treatment (HT) administered to 670 newborns (84.4%)
Number of subjects: 794
Study 36272997 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors associated with death
Number of subjects: 794
Study 36272997 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological status
Number of subjects: 794
Study 36273191 — intervention group
Group type: EXPERIMENTAL
Intervention: Mr. MAPP (Mixed reality system for Managing Phantom Pain)
Number of subjects: 7
Study 36273204 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing emotionally expressive faces
Number of subjects: 0
Study 36273221 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored motivational interviewing
Number of subjects: 128
Study 36273221 — intervention group
Group type: COMPARATOR
Intervention: Individually focused HIV prevention intervention
Number of subjects: 128
Study 36273324 — intervention group
Group type: EXPERIMENTAL
Intervention: FLASH radiotherapy (≥40 Gy/sec)
Number of subjects: 10
Study 36273324 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (conventional-dose-rate photon radiotherapy at approximately 0.03 Gy/sec)
Number of subjects: 10
Study 36273417 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided deferred-PCI with abnormal resting Pd/Pa
Number of subjects: 1134
Study 36273417 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided deferred-PCI with abnormal CFR
Number of subjects: 1134
Study 36273417 — intervention group
Group type: EXPERIMENTAL
Intervention: Age correlation with FFR
Number of subjects: 1134
Study 36273417 — intervention group
Group type: EXPERIMENTAL
Intervention: Age correlation with resting Pd/Pa
Number of subjects: 1134
Study 36273417 — intervention group
Group type: EXPERIMENTAL
Intervention: Age correlation with CFR
Number of subjects: 1134
Study 36273822 — intervention group
Group type: EXPERIMENTAL
Intervention: M3258, an orally bioavailable, potent, selective, reversible inhibitor of LMP7
Number of subjects: 0
Study 36273986 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted influenza A/H7N9 vaccine
Number of subjects: 37
Study 36273986 — intervention group
Group type: COMPARATOR
Intervention: Unadjuvanted influenza A/H7N9 vaccine
Number of subjects: 37
Study 36274108 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (GA)
Number of subjects: 347
Study 36274108 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin during the procedure
Number of subjects: 347
Study 36274108 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission NIHSS ≥ 26
Number of subjects: 347
Study 36274108 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from onset to puncture (OTP) ≥ 395 min
Number of subjects: 347
Study 36274108 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure duration ≥ 102 min
Number of subjects: 347
Study 36274108 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission NIHSS > 36 vs. ≤ 11
Number of subjects: 347
Study 36274108 — intervention group
Group type: EXPERIMENTAL
Intervention: OTP > 441 min vs. ≤ 210 min
Number of subjects: 347
Study 36274108 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure duration > 145 min vs. ≤ 59 min
Number of subjects: 347
Study 36274113 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable compensated cirrhosis (CC) patients
Number of subjects: 28
Study 36274113 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (HV)
Number of subjects: 28
Study 36274161 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptolide
Number of subjects: 0
Study 36274161 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 0
Study 36274161 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanosine
Number of subjects: 0
Study 36274161 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF
Number of subjects: 0
Study 36274263 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic donor lymphocyte infusion (DLI) administered at 30 days after transplantation for HLA-matched related HSCT or at 45-60 days for haploidentical/unrelated HSCT.
Number of subjects: 105
Study 36274263 — intervention group
Group type: COMPARATOR
Intervention: Standard of care therapy (control group).
Number of subjects: 105
Study 36274263 — intervention group
Group type: EXPERIMENTAL
Intervention: Total therapy (including allo-HSCT and prophylactic DLI).
Number of subjects: 105
Study 36274573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg) administered every 2 weeks until disease progression, unacceptable toxicity, or 12 months of treatment.
Number of subjects: 24